Jay Shepard returned to Sofinnova as a Executive Partner, following the successful sale of Sofinnova portfolio company NextWave Pharmaceuticals to Pfizer. Jay served as President and CEO of NextWave since early 2010. He has more than 25 years’ experience in the pharmaceutical, biotechnology and drug delivery arenas. Jay originally joined Sofinnova in 2008, as an Executive in Residence.
Prior to Sofinnova Ventures, Jay was President and CEO of Ilypsa, a nephrology therapeutics company acquired by Amgen for $420 million. He then helped with Ilypsa's spin-out of Relypsa, serving as interim President and CEO. Before Ilypsa, Jay served as Vice President of Commercial Operations at Telik, where he was responsible for all activities relating to market preparation toward the launch of the company's lead oncology compounds. He was also Vice President of ALZA Pharmaceuticals' Oncology Business Unit, having held leadership positions of increasing responsibility in the establishment and operation of ALZA's specialty pharmaceutical sales and marketing group. Jay began his career in pharmaceutical sales and marketing at Ortho Pharmaceutical and Syntex Laboratories.
Jay holds a B.S. in Business Administration from the University of Arizona